Business
Half Yearly Report
Half Yearly Report.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 9936I IXICO plc 06 June 2014 \n \n\n \n6 June 2014\n \nInterim results to 31 March 2014\n \nSuccessful launch of Assessa® - significant progress in clinical trials and experimental medicine business\n \nIXICO plc (Ticker: IXI) (\"IXICO\" or the \"Company\"), the brain health company, today announces its unaudited interim results for the six months ended 31 March 2014.\n \nHighlights\n \n· Successful launch of Assessa®, our CE-marked digital healthcare platform for decision-support in dementia diagnosis\no IXICO and partner InHealth providing selective access to Assessa® in the UK and Eire\no Assessa® now available in the private healthcare sector through Re:Cognition Health Limited\no Krish Ramakrisnan appointed as Vice President, Product Marketing with specific responsibility for the commercialisation of Assessa®\no Further investment in the development and commercialisation of Assessa®\n \n· Expansion in clinical trials and experimental medicine business\no Contracts signed with four new customers; IXICO has now been awarded contracts by nine of the top fifteen global pharmaceutical companies\no International commercial and operational alliance signed with VirtualScopics of the US to deliver world-class services to pharmaceutical, biotech and academic customers and collaborators around the globe\n \n· Continuing business development in China\no Memorandum of Understanding signed with Beijing Union Medical and Pharmaceutical General Corporation, the innovation arm of the Chinese Academy of Medical Sciences during the UK Prime Minister's trade mission to China\no IXICO subsequently awarded its first Phase III clinical trial with a local Chinese pharmaceutical company\no Asia developing as a key strategic priority for IXICO\n \n· Financial performance on budget and in-line with expectations\no Revenues of £1.2 million and operating loss before non-recurring expenses of £0.6 million for the period\no Total cash and money market investments of £4.0 million as at 31 March 2014\n \nRecent Developments\n \n· Awarded a development contract by The...